Pharmacoeconomics: Cost of Illness Studies
نویسنده
چکیده
Cost-of-illness studies measure the economic burden of a disease and estimate the maximum amount that could potentially be saved or gained if a disease were to be eradicated. Direct medical costs and indirect costs are measured using top down and bottom up approaches Human Capital approach, Willingness-to-Pay (WTP) approach and Friction Costs approach respectively. The perspectives may measure costs to society, the health care system, third-party payers, businesses, the government, and participants and their families. Incidencebased studies, estimate lifetime costs, measure the costs of an illness from onset to conclusion for cases beginning within the period of the study, usually a year. Incidence costs include the discounted, lifetime medical, morbidity, and mortality costs for the incident cohort. Prevalence-based studies measure the costs of an illness in a year, regardless of the date of onset and include all medical care costs and morbidity costs for a disease. Indirect costs include the loss of resources due to morbidity and mortality, which inherently places a monetary value on the value of life. The human capital method is the most common approach used to calculate the indirect costs of an illness. The costs attributable to an illness depend largely on how the illness is defined diagnostically. Studies typically use the International Classification of Diseases, as a basis of defining the illness of interest and whether to include secondary diagnoses. The appropriate data source to use for a cost-of-illness study varies by the illness, perspective, and approach of the study.
منابع مشابه
Patient Benefits And Cost Savings Predicted For Mineralocorticoid-Receptor Antagonist Treatment Of Early And Advanced Diabetic Kidney Disease.
Limitations and uncertainties of the model findings are around (1) the correlation between albuminuria and outcomes; this correlation has been shown in retrospect but not in prospective studies; (2) outcome predictors, due to the absence of phase 3 data on finerenone‟s clinical effectiveness to change clinical outcomes; (3) availability of data for progression to macroalbuminuria, due to low ...
متن کاملCost of Illness Study of Type 2 Diabetes Mellitus in the Newly Established Diabetology Outpatient Facility in the Czech Republic.
متن کامل
Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation.
Investigating the pharmacoeconomic impact of any diagnostic or therapeutic intervention in the Irish healthcare setting is currently compromised by the lack of detailed cost data. Consequently, we conducted a number of microcosting studies in the areas of acute myocardial infarction, cardiac failure and HIV, from the hospital perspective. The results of these microcosting studies were compared ...
متن کاملPharmacoeconomics of Helicobacter pylori: eradication versus maintenance therapy in controlling peptic ulcer disease.
We performed an electronic search in Medline and EMBASE for papers comparing Helicobacter pylori eradication and H(2)RA-maintenance therapy in peptic ulcer. Treatment to eradicate H. pylori in patients with a proven ulcer has a favorable cost-effectiveness compared with maintenance therapy, with benefits for the patient and society. In most studies, it was assumed that no more gastrointestinal ...
متن کاملKey Cost Drivers Of Type 2 Diabetes Mellitus: an International Literature Review.
Type 2 Diabetes Mellitus (T2DM) is a worldwide chronic disease, related to high morbidity and mortality, and to significant quality of life deterioration. It is frequently associated not only with acute decompensations but also with chronic complications such as cardiovascular problems, renal disease, neuropathy, foot ulcer and loss of vision. The existence of comorbidities and complications no...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2009